| Outcome Measures: |
Primary: Difference in HbA1c change from baseline (%) among SIDD, SIRD, MARD, MOD subtypes, Difference in HbA1c change from baseline will be evaluated at first follow-up visit (occurring 6-12 months from GLP-1RA initiation) | Secondary: Difference in time to failure among SIDD, SIRD, MARD, MOD subtypes, In patients reaching HbA1c \<7% at first follow-up visit, the difference in time to failure (defined as HbA1c equal or above 7%), Difference in time to failure will be assessed up to the last available visit (up to 36 months)|Difference in fasting blood glucose change from baseline (mg/dl) among SIDD, SIRD, MARD, MOD subtypes, mg/dl, Difference in fasting blood glucose change from baseline (mg/dl) will be evaluated at first follow-up visit (occurring 6-12 months from GLP-1RA initiation)|Difference in body weight change from baseline (kg) among SIDD, SIRD, MARD, MOD subtypes, kg, Difference in body weight change from baseline (kg) will be evaluated at first follow-up visit (occurring 6-12 months from GLP-1RA initiation)|Difference in percentage of patients reaching HbA1c below 7% among SIDD, SIRD, MARD, MOD subtypes, Difference in percentage of patients reaching HbA1c below 7% will be evaluated at first follow-up visit (occurring 6-12 months from GLP-1RA initiation)
|
